Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss

18 August 2026 · By · Wire by Fusion42

Published

18 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 21 August 2026 · Fusion42 review

Kolon TissueGene is laying off 37 employees after its phase 3 trial for the osteoarthritis therapy TG-C failed to meet co-primary endpoints, causing the company to realign its business priorities.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Biotech founders developing cell and gene therapies must prepare for tougher Phase 3 trial scrutiny and ready fallback plans as Kolon TissueGene’s failure and workforce cut reveal clinical risk and funding pressure.

◆ Coverage

1 source · 18 Aug 2026

◆ Related on Wire

◆ Topics

Biotechbiotechosteoarthritisclinical-triallayoffscell-gene-therapy